Blog


Valeant Pharmaceuticals Settles Securities Fraud Class Action for $1.21 Billion

Second Mega Settlement For 2020



Good news for those investors who purchased Valeant securities between February 28, 2014 and October 21, 2015. Plaintiffs and Valeant (now known as Bausch Health) have hammered out a $1.21 billion settlement. Settlement notices and claim forms are not yet available, but Chicago Clearing Corporation (CCC) will begin preparing claims for our clients as soon as they are. (This is the second mega-settlement, or settlement over $1 billion, so far for 2020. The other is American Realty Capital Properties, which settled for $1.025 billion.)  

What this case is about

In December 2015, plaintiffs filed a class action complaint alleging, among other things, that Valeant “made numerous false and misleading statements during the Class Period” and that they “formed a secret network of so-called specialty pharmacies to artificially inflate the sale of Valeant drugs using a variety of fraudulent practices.” You are not supposed to do that.

“As part of the Settlement,” notes Bausch Health’s press release announcing the settlement, “The Company and the other settling defendants admit no liability and deny all allegations of wrongdoing whatsoever.” So there.

How CCC Can Help

In a similar class action now pending in Canada, plaintiffs identified not only the common stock of Valeant but notes and debt as eligible securities. While the definitive list of securities eligible in this litigation will not be clear until the settlement notice appears, it is possible that an array of securities types will be also be eligible here. CCC can help you identify every last transaction and position for every account, and ensure that every eligible claim is submitted correctly and promptly. From the date we file the claim and through the distribution, we will communicate with the claims administrator to ensure your claim receives the compensation it deserves.


More News from the Class Action World




In a recent post, we discussed the first two settlements in the GSE Bonds Antitrust litigation which then totaled $49.5 million. (Well, $29.5 Million was the initial settlement amount, as... Read More

Good news for those investors who purchased Valeant securities between February 28, 2014 and October 21, 2015. Plaintiffs and Valeant (now known as Bausch Health) have hammered out a $1.21 billion settlement. Settlement notices and claim forms are not yet available, but Chicago Clearing Corporation (CCC) will begin preparing claims f... Read More

Did you trade debt securities of government sponsored enterprises (aka GSE bonds) between 2009 and 2019? If so, you may be eligible to participate in an antitrust settlement.

Plaintiffs allege that the defendants (see full list below) conspired to fix prices of unsecured GSE bonds issued by Federal ... Read More

Case Name: Akorn 2019 Securities Settlement

Settlement Fund: Between $53.6 million and $155.4 Million

Claim Filing Deadline: January 24, 2020

Class Period: 11/3/2016 – 1/8/2019

Read More

Endo International... Sound familiar? Earlier this August we posted a blog with a similar title “Endo International Settles Securities Settlement for $50 Million.”

So what’s the difference? Aside from $32.5 million.

The first settlement pertained to declining demand for Endo’s generic drugs and also alleged th... Read More

Investors in American Realty Capital Properties (ARCP), now known as Vereit, may be eligible for a massive settlement that could pay as much as 50% of damages. Given that the typical recovery is just 2%, this is great news for harmed ARCP investors.

What is this case about?

ARCP was an investment services firm fou... Read More